Storia in 3 fonti

FDA Expands Label of Oral HIV Drug to Newborns

Dolutegravir is already approved as combination therapy in adults and older children

Raccontata da

healio.com

medpagetoday.com

morningstar.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo4 g fa

FDA Expands Label of Oral HIV Drug to Newborns

Dolutegravir is already approved as combination therapy in adults and older children

originale

healio.com6 g fa

FDA extends approval of Tivicay to treat newborns with HIV

The FDA has extended its approval of dolutegravir tablets for oral suspension to treat newborns with HIV. Dolutegravir tablets (Tivicay, ViiV Healthcare) and dolutegravir tablets for oral suspension (Tivicay PD, ViiV)…

Leggi questa versione → originale

Timeline cronologica

martedì 25 agosto 2026·healio.com
FDA extends approval of Tivicay to treat newborns with HIV
The FDA has extended its approval of dolutegravir tablets for oral suspension to treat newborns with HIV. Dolutegravir tablets (Tivicay, ViiV Healthcare) and dolutegravir tablets…
mercoledì 26 agosto 2026·medpagetoday.com
FDA Expands Label of Oral HIV Drug to Newborns
Dolutegravir is already approved as combination therapy in adults and older children

FDA Expands Label of Oral HIV Drug to Newborns

Confronto fonti

FDA Expands Label of Oral HIV Drug to Newborns

FDA extends approval of Tivicay to treat newborns with HIV

Timeline cronologica

FDA extends approval of Tivicay to treat newborns with HIV

FDA Expands Label of Oral HIV Drug to Newborns

U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children

U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children